Drug intelligence / Profile preview

NAL1872

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

NAL1872 is a liposomal formulation of the anthracycline chemotherapy agent doxorubicin, currently in preclinical development by NAL Pharmaceutical Group. As a liposomal injection, it is designed to optimize the pharmacokinetic profile of doxorubicin, potentially enhancing tumor delivery while reducing systemic toxicities, such as cardiotoxicity, that are commonly associated with conventional doxorubicin formulations. The active ingredient, doxorubicin, acts by intercalating between DNA base pairs and inhibiting the enzyme topoisomerase II, which prevents DNA ligation and leads to the induction of apoptosis in rapidly dividing cancer cells. NAL1872 is being investigated for applications in oncology and supportive oncology.

Other names: Doxorubicin LiposomeDoxorubicin

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on NAL1872.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL1872.

Explore the full profile